Definition · Plain-language
Biologics License Application (BLA)
A Biologics License Application (BLA) is the formal request to the US Food and Drug Administration for permission to introduce a biological product into interstate commerce, submitted under the Public Health Service Act.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
What a BLA is for
A Biologics License Application is the regulatory submission through which a sponsor seeks authorisation to market a biological product — a class that includes vaccines, blood and blood components, allergenics, gene and cell therapies, and many therapeutic proteins such as monoclonal antibodies. Unlike small-molecule drugs, which are marketed under a New Drug Application, biologics are licensed under section 351 of the Public Health Service Act. A granted BLA results in a biologics licence permitting the product to enter interstate commerce, rather than an approved drug application in the strict statutory sense.
What the application must show
A BLA must contain data establishing that the biological product is safe, pure and potent, along with a full description of the manufacturing process, the facilities involved and the controls used to ensure consistent quality. Because biologics are typically large, complex molecules produced in living systems, manufacturing characterisation carries particular weight. The application assembles non-clinical and clinical study results, labelling and chemistry, manufacturing and controls information so that reviewers can assess both the product and the process that makes it.
Who reviews and approves it
BLAs are reviewed by the FDA, historically by the Center for Biologics Evaluation and Research (CBER). Following an administrative transfer, certain therapeutic biologics — including many monoclonal antibodies and therapeutic proteins — are now reviewed by the Center for Drug Evaluation and Research (CDER), while vaccines, blood products and cell and gene therapies remain with CBER. Approval is signified by issuing a biologics licence. The pathway sits alongside the abbreviated 351(k) route used for biosimilar and interchangeable products.
Key facts
At a glance
- Definition: Application to market a biological product in the United States.
- Stands for: Biologics License Application.
- Statute: Public Health Service Act, section 351.
- Standard: Product must be safe, pure and potent.
- Reviewer: FDA — CBER, or CDER for certain therapeutic biologics.
- Outcome: FDA issues a biologics licence (a licensure, not an NDA approval).
Common misconceptions
What people often get wrong
Often heard: A BLA is just the biologics version of a New Drug Application under the same statute.
Actually: They differ in legal basis. A BLA is submitted under section 351 of the Public Health Service Act, whereas a New Drug Application is submitted under the Federal Food, Drug, and Cosmetic Act. The standards and resulting authorisations are distinct.
Often heard: All biologics are reviewed by CBER.
Actually: Many therapeutic biologics, such as monoclonal antibodies and therapeutic proteins, are reviewed by CDER following an administrative transfer. CBER continues to review vaccines, blood products and cell and gene therapies.
Often heard: Biosimilars are approved through a standard BLA.
Actually: Biosimilar and interchangeable products use the abbreviated 351(k) pathway, which relies on demonstrating similarity to an already-licensed reference product, rather than a standalone full BLA under 351(a).
